Evidence map›Paper›PMID 35157996›Full record

ArticleInternational journal of radiation oncology, biology, physics2022

Effects of Tumor Mutational Burden and Gene Alterations Associated with Radiation Response on Outcomes of Postoperative Radiation Therapy in Non-Small Cell Lung Cancer.

Narek Shaverdian, Annemarie F Shepherd, Xingzhe Li, Michael Offin, Harry B Lengel, Daphna Y Gelblum, Abraham J Wu, Charles B Simone, Andreas Rimner, David R Jones and 3 more

Open access · greenAbstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Variable cellular and radiobiological effects of [Journal of experimental & clinical cancer research : CR · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024
    Article
  11. Article
  12. Review
  13. Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Narek ShaverdianDepartment of Radiation Oncology. Electronic address: shaverdn@mskcc.org.
Annemarie F ShepherdDepartment of Radiation Oncology.
Xingzhe LiDepartment of Radiation Oncology.
Michael OffinThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine.
Harry B LengelDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Daphna Y GelblumDepartment of Radiation Oncology.
Abraham J WuDepartment of Radiation Oncology.
Charles B SimoneDepartment of Radiation Oncology.
Andreas RimnerDepartment of Radiation Oncology.
David R JonesDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Jamie E ChaftThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine.
Nadeem RiazDepartment of Radiation Oncology.
Daniel R GomezDepartment of Radiation Oncology.
Memorial Sloan Kettering Cancer Center · USMSD K.K. (Japan) · JP

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Training in Child Health Services Research and Implementation ScienceT32HS000063 · AHRQ · CHILDREN'S HOSPITAL BOSTON · PI GARABEDIAN, LAURA FADEN, WALSH, KATHLEEN ELIZABETH · 1994 to 2024
$7.6M
AHRQ HHS T32 HS000063NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposePostoperative radiation therapy (PORT) in resected non-small cell lung cancer (NSCLC) improves locoregional outcomes, but recent randomized data do not support its unselected use. We assessed if tumor mutational burden (TMB) and mutations in genes associated with radiation sensitivity can select patients for PORT. METHODS AND MATERIALS: Patients with resected NSCLC treated with and without PORT who underwent tumor genomic profiling were examined. The incidence of locoregional failures (LRFs) in patients with deleterious mutations in DNA damage response and repair (DDR) genes and genes associated with radiation resistance (KEAP1/NFE2L2/STK11/PIK3CA) were investigated. Cox modeling and receiver operating characteristic curve (ROC) analysis assessed the relationship between TMB and locoregional control (LRC).

resultsEighty-nine patients with NSCLC treated with PORT were analyzed, with a 2-year LRF rate of 19% (95% confidence interval, 10%-27%). Among patients treated with PORT, those with mutations in radiation resistance genes (n = 16 [18%]) had significantly more LRFs than patients without mutations (2-year LRF rate: 60% vs 11%; P < .001). On multivariate analysis, radiation-resistance mutations were associated with LRF after PORT (hazard ratio, 7.42; P < .001). Patients with mutations identified in DDR genes (n = 15 [17%]) had significantly improved LRC (P = .048) and no LRF events after PORT. On multivariate analysis, a higher TMB was associated with improved LRC after PORT (hazard ratio, 0.86; P = .01), and TMB was associated with PORT outcomes (area under ROC curve, 0.67-0.77). These genomic markers were not similarly associated with LRF in patients not treated with PORT.

conclusionsThe data suggest that patients with radiation-resistance gene alterations may derive minimal benefit from PORT, whereas patients with high TMB and/or alterations in DDR genes may benefit from PORT and be suited for future precision-RT strategies. Prospective studies are necessary to validate these findings.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorHumansKelch-Like ECH-Associated Protein 1MutationNF-E2-Related Factor 2Prospective StudiesBiomarkers, TumorKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2

Identifiers

PMID35157996
PMCPMC9976944
OpenAlexW4211024284

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.